Esperion Therapeutics Inc (NASDAQ:ESPR) major shareholder Target N. V. Biotech bought 80,000 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were acquired at an average price of $33.78 per share, for a total transaction of $2,702,400.00. Following the completion of the transaction, the insider now directly owns 3,652,964 shares in the company, valued at approximately $123,397,123.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

NASDAQ:ESPR traded down $0.69 during mid-day trading on Friday, hitting $34.83. 11,116 shares of the stock traded hands, compared to its average volume of 449,768. The stock has a market capitalization of $936.57 million, a price-to-earnings ratio of -4.62 and a beta of 1.71. Esperion Therapeutics Inc has a 52 week low of $33.13 and a 52 week high of $60.99. The firm’s 50 day moving average is $38.79 and its two-hundred day moving average is $44.59. The company has a quick ratio of 5.65, a current ratio of 5.65 and a debt-to-equity ratio of 0.01.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($1.86) by ($0.15). The company had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.05 million. The company’s revenue was up 9720.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.71) EPS. As a group, research analysts predict that Esperion Therapeutics Inc will post -3.02 EPS for the current year.

ESPR has been the topic of several recent research reports. Northland Securities restated a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, August 29th. Stifel Nicolaus restated a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, June 13th. Goldman Sachs Group cut shares of Esperion Therapeutics from a “neutral” rating to a “sell” rating and set a $50.00 target price on the stock. in a research report on Wednesday, May 29th. BidaskClub cut shares of Esperion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 31st. Finally, Citigroup set a $73.00 target price on shares of Esperion Therapeutics and gave the company a “buy” rating in a research report on Tuesday, May 28th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $74.00.

A number of large investors have recently modified their holdings of the stock. Pictet Asset Management Ltd. grew its stake in Esperion Therapeutics by 13.6% in the 1st quarter. Pictet Asset Management Ltd. now owns 437,518 shares of the biopharmaceutical company’s stock worth $17,566,000 after acquiring an additional 52,467 shares in the last quarter. Wasatch Advisors Inc. grew its stake in Esperion Therapeutics by 13.4% in the 1st quarter. Wasatch Advisors Inc. now owns 637,789 shares of the biopharmaceutical company’s stock worth $25,607,000 after acquiring an additional 75,165 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Esperion Therapeutics by 4.3% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 44,225 shares of the biopharmaceutical company’s stock worth $1,776,000 after acquiring an additional 1,825 shares in the last quarter. Spark Investment Management LLC grew its stake in Esperion Therapeutics by 72.1% in the 1st quarter. Spark Investment Management LLC now owns 390,900 shares of the biopharmaceutical company’s stock worth $15,694,000 after acquiring an additional 163,800 shares in the last quarter. Finally, Pinnacle Associates Ltd. grew its stake in Esperion Therapeutics by 4.0% in the 2nd quarter. Pinnacle Associates Ltd. now owns 187,549 shares of the biopharmaceutical company’s stock worth $8,725,000 after acquiring an additional 7,225 shares in the last quarter. Institutional investors own 98.93% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

See Also: What is Compound Interest?

Insider Buying and Selling by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.